BRAIN Biotech AG Financial Results H1 2024 / 25 | Innovation Momentum and Strategic Focus

BRAIN Biotech AG Q1 2024/25: Key TakeawaysBRAIN Biotech AG H1 FY 2024/25: Innovation Momentum and Strategic FocusPresented by Michael Schneiders, Chief Financial OfficerIn this strategic and transparent financial update, Michael Schneiders, Chief Financial Officer of BRAIN Biotech AG, guides investors through the company’s final H1 FY 2024/25 results, providing insights into both operational progress and long-term positioning in the industrial biotechnology sector.Revenue Stability and Margin StrengthDespite macroeconomic challenges, BRAIN Biotech AG has demonstrated resilience, with group revenue reaching €27.3 million, a modest year-over-year increase of 1.5%. This growth was primarily driven by the BioScience segment, which posted double-digit growth, and the company maintained a solid gross margin of 31.6%, a testament to our favourable product mix and operational efficiency gains.Segment HighlightsThe BioScience division, focused on R&D services and tailor-made enzyme solutions, continues to thrive. With strong project demand and recurring customer business, this segment remains the primary growth engine and a testament to BRAIN’s unwavering commitment to innovation-driven strategy.The BioIndustrial segment, which includes proprietary product sales, showed a temporary decline due to destocking effects in the nutritional ingredients business. However, CFO Michael Schneiders highlights that this is expected to normalize in the second half of the fiscal year.Strategic Innovation: Akribion GenomicsOne of the strategic highlights of the presentation is the continued progress in BRAIN’s genome editing platform, particularly within Akribion Genomics, a BRAIN subsidiary focused on CRISPR-based cell targeting technologies. The company recently strengthened its IP portfolio and is progressing toward preclinical validation, positioning itself for potential out-licensing and industrial applications.Key Financial Metrics- Adjusted EBITDA at €0.6 million, showing positive operational leverage- Improved cost structure, with lower R&D and admin expenses compared to last year- Cash and equivalents at €9.4 million, ensuring liquidity for innovation and growthFY 2024/25 OutlookBRAIN Biotech confirms its full-year 2024/25 guidance, expecting:- Group revenue growth in the mid-single-digit percentage range- Further expansion in the BioScience segment- Strong progress on strategic partnerships and tech licensing modelsStrategic Transformation and Growth PathCFO Schneider emphasizes that BRAIN is transitioning from a pure service model to a dual-track model, combining revenue from both high-margin services and scalable biotech innovations. This strategic shift underscores the company’s focus on unlocking value through deep-tech enzyme engineering, sustainable bioprocesses, and advanced genome editing, instilling confidence in our future direction.Conclusion: A Future-Driven Biotech EnablerThe presentation concludes with a confident outlook, reaffirming BRAIN Biotech’s ambition to become a leading enabler in industrial biotechnology, particularly in green transformation, food innovation, and medical bioengineering.▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.